Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724867 · ClinicalTrials.gov registry record · Phase 3
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Phase 3 study, sponsored by Human Genome Sciences Inc., a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
NCT00724867: Completed Phase 3 study, sponsored by Human Genome Sciences Inc., a GSK Company.
NCT00724867 is a Phase 3 study that has completed, run by Human Genome Sciences Inc., a GSK Company. The registered enrollment target is 268 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00724867, a Phase 3 study, has completed, sponsored by Human Genome Sciences Inc., a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
Study Summary
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.
Primary Outcome
An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires
Interventions
- BIOLOGICAL Belimumab 10 mg/kg
- BIOLOGICAL Belimumab 1 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2008-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
What the finished NCT00724867 record still lists
NCT00724867 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Belimumab 10 mg/kg is the first listed.
NCT00724867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00724867 about?
NCT00724867 is a clinical study titled "A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States". This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.
What is the current status of trial NCT00724867?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 2008-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00724867?
The interventions under investigation include: Belimumab 10 mg/kg (BIOLOGICAL), Belimumab 1 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00724867?
This trial is sponsored by Human Genome Sciences Inc., a GSK Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00724867's enrollment target sits among peer trials
268 1222nd of 2000 higher than 779 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia